The Vigabatrin REMS Program is needed by the FDA to guarantee notified risk-benefit decisions before initiating therapy, and to make certain appropriate use of vigabatrin while patients are treated. It is not possible for your healthcare provider to recognize when vision loss will certainly happen.
It is suggested that your healthcare provider test your (or your child's) vision prior to or within 4 weeks after beginning SABRIL and a minimum of every 3 months during treatment up until SABRIL is quit. Inform your doctor if you or your child have any kind of adverse effects that troubles you or that does not go away.
Inform your healthcare provider as soon as possible if seizures worsen. You and your healthcare provider will have to decide if you should take SABRIL while you are expecting. The most common adverse effects of SABRIL in grownups consist of: obscured vision, sleepiness, dizziness, problems strolling or feeling uncoordinated, drinking (tremor), and tiredness.